| pubmed-article:1343617 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1343617 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:1343617 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1343617 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:1343617 | lifeskim:mentions | umls-concept:C0278883 | lld:lifeskim |
| pubmed-article:1343617 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:1343617 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:1343617 | pubmed:dateCreated | 1994-3-17 | lld:pubmed |
| pubmed-article:1343617 | pubmed:abstractText | Based upon their individual clinical activity and combined effects in animal models or in vitro, we wished to evaluate a regimen of cisplatin, interferon-alpha, and IL-2 in patients with metastatic melanoma. | lld:pubmed |
| pubmed-article:1343617 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1343617 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1343617 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1343617 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1343617 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1343617 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1343617 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1343617 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1343617 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1343617 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1343617 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:1343617 | pubmed:issn | 1059-2725 | lld:pubmed |
| pubmed-article:1343617 | pubmed:author | pubmed-author:LongoD LDL | lld:pubmed |
| pubmed-article:1343617 | pubmed:author | pubmed-author:SteinR LRL | lld:pubmed |
| pubmed-article:1343617 | pubmed:author | pubmed-author:BeveridgeJJ | lld:pubmed |
| pubmed-article:1343617 | pubmed:author | pubmed-author:UrbaW JWJ | lld:pubmed |
| pubmed-article:1343617 | pubmed:author | pubmed-author:FentonR GRG | lld:pubmed |
| pubmed-article:1343617 | pubmed:author | pubmed-author:CreekmoreS... | lld:pubmed |
| pubmed-article:1343617 | pubmed:author | pubmed-author:JanikJ EJE | lld:pubmed |
| pubmed-article:1343617 | pubmed:author | pubmed-author:SznolMM | lld:pubmed |
| pubmed-article:1343617 | pubmed:author | pubmed-author:SmithJ WJW2nd | lld:pubmed |
| pubmed-article:1343617 | pubmed:author | pubmed-author:SharfmanW HWH | lld:pubmed |
| pubmed-article:1343617 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:1343617 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:1343617 | pubmed:volume | Doc No 9 | lld:pubmed |
| pubmed-article:1343617 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1343617 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1343617 | pubmed:pagination | [3841 words; 32 paragraphs] | lld:pubmed |
| pubmed-article:1343617 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:1343617 | pubmed:meshHeading | pubmed-meshheading:1343617-... | lld:pubmed |
| pubmed-article:1343617 | pubmed:meshHeading | pubmed-meshheading:1343617-... | lld:pubmed |
| pubmed-article:1343617 | pubmed:meshHeading | pubmed-meshheading:1343617-... | lld:pubmed |
| pubmed-article:1343617 | pubmed:meshHeading | pubmed-meshheading:1343617-... | lld:pubmed |
| pubmed-article:1343617 | pubmed:meshHeading | pubmed-meshheading:1343617-... | lld:pubmed |
| pubmed-article:1343617 | pubmed:meshHeading | pubmed-meshheading:1343617-... | lld:pubmed |
| pubmed-article:1343617 | pubmed:meshHeading | pubmed-meshheading:1343617-... | lld:pubmed |
| pubmed-article:1343617 | pubmed:meshHeading | pubmed-meshheading:1343617-... | lld:pubmed |
| pubmed-article:1343617 | pubmed:meshHeading | pubmed-meshheading:1343617-... | lld:pubmed |
| pubmed-article:1343617 | pubmed:meshHeading | pubmed-meshheading:1343617-... | lld:pubmed |
| pubmed-article:1343617 | pubmed:meshHeading | pubmed-meshheading:1343617-... | lld:pubmed |
| pubmed-article:1343617 | pubmed:meshHeading | pubmed-meshheading:1343617-... | lld:pubmed |
| pubmed-article:1343617 | pubmed:meshHeading | pubmed-meshheading:1343617-... | lld:pubmed |
| pubmed-article:1343617 | pubmed:meshHeading | pubmed-meshheading:1343617-... | lld:pubmed |
| pubmed-article:1343617 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1343617 | pubmed:articleTitle | Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II Study. | lld:pubmed |
| pubmed-article:1343617 | pubmed:affiliation | Clinical Research Branch, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21701. | lld:pubmed |
| pubmed-article:1343617 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1343617 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1343617 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1343617 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
